Post Reply
181-200 of 4747
Substantial shareholder Mr Ong bailed out by Mr Wong
Tob231 ( Date: 13-Jun-2025 11:16) Posted:
|
Some traders got stuck .... misfired
announcements made lately. positive vibes
Got volume is it 1 day wonder?
The privatisation offer for this small Catalist company could cause SGX some discomfort
https://www.businesstimes.com.sg/opinion-features/privatisation-offer-small-catalist-company-could-cause-sgx-some-discomfort
On May 28, the group received a cash offer ? via a scheme arrangement at S$0.16 a share from Advance Bridge Healthcare, a special-purpose vehicle owned by Singapore Paincare?s founder and chief executive, Dr Bernard Lee, and its chief operating officer, Dr Jeffrey Loo.
On May 28, the group received a cash offer ? via a scheme arrangement at S$0.16 a share from Advance Bridge Healthcare, a special-purpose vehicle owned by Singapore Paincare?s founder and chief executive, Dr Bernard Lee, and its chief operating officer, Dr Jeffrey Loo.
https://www.businesstimes.com.sg/opinion-features/privatisation-offer-small-catalist-company-could-cause-sgx-some-discomfort
On May 28, the group received a cash offer ? via a scheme arrangement at S$0.16 a share from Advance Bridge Healthcare, a special-purpose vehicle owned by Singapore Paincare?s founder and chief executive, Dr Bernard Lee, and its chief operating officer, Dr Jeffrey Loo.
On May 28, the group received a cash offer ? via a scheme arrangement at S$0.16 a share from Advance Bridge Healthcare, a special-purpose vehicle owned by Singapore Paincare?s founder and chief executive, Dr Bernard Lee, and its chief operating officer, Dr Jeffrey Loo.
looks legit and huge
xianwe ( Date: 21-May-2025 11:27) Posted:
|
No.
Maybe, if list in China
Maybe, if list in China
xianwe ( Date: 23-May-2025 17:19) Posted:
|
Will clearbridge become the next jiangsu heng rui. Lets see
Jiangsu Hengrui makes solid Hong Kong trading debut as shares jump 29%
Jiangsu Hengrui makes solid Hong Kong trading debut as shares jump 29%
Good stuff have to wait....now chip chip... CV ollecting now gor future psyout
shk363 ( Date: 21-May-2025 19:16) Posted:
|
very long almost a year to wait for the RTO
bernardc ( Date: 21-May-2025 11:48) Posted:
|
Mou signed...conducting n preparing contract..stop date 279 days after mou
Tob231 ( Date: 05-May-2025 10:08) Posted:
|
Elpis Biopharmaceuticals to Present New Data on Multi-Mechanism Armored CAR-T Therapy at PEGS Summit 2025
LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced that Founder and CEO Yan Chen, MD, PhD, will present new preclinical data on the company' s proprietary multi-mechanism armored CAR-T platform at the PEGS Protein & Antibody Engineering Summit on May 14, 2025, in Boston.
In the presentation, " Multi-Mechanism Armored CAR-T Effectively Overcomes Tumor Microenvironment Resistance and Eradicates Solid Tumors," Dr. Chen will highlight the discovery of Elpis' s multi-mechanism armor by fusing a precision-engineered IL-2 molecule to an anti-PD-L1 antibody, which has the potential to simultaneously overcome multiple resistance mechanisms within the tumor microenvironment (TME). The platform is designed to activate bystander immune cells, selectively target key immune cell types, and orchestrate the immune system for a durable anti-tumor response.
Elpis' s human bispecific armored CAR-T cells have demonstrated potent tumor regression, long persistence, and robust immune modulation across multiple solid tumor models&mdash all at significantly lower doses. These attributes reflect the platform' s potential to improve drugability, safety and support more durable clinical outcomes.
" This is an exciting moment for Elpis," said Dr. Chen. " Our multi-mechanism armor is the result of years of innovation in precision cytokine engineering empowered by mRNA display technology. By addressing both TME resistance with armored cytokine and tumor heterogeneity through bispecific targeting, our platform has the potential to deliver safer, more effective and persistent CAR-T therapies in solid tumors."
Elpis Biopharmaceuticals to Present New Data on Multi-Mechanism Armored CAR-T Therapy at PEGS Summit 2025
LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced that Founder and CEO Yan Chen, MD, PhD, will present new preclinical data on the company' s proprietary multi-mechanism armored CAR-T platform at the PEGS Protein & Antibody Engineering Summit on May 14, 2025, in Boston.
In the presentation, " Multi-Mechanism Armored CAR-T Effectively Overcomes Tumor Microenvironment Resistance and Eradicates Solid Tumors," Dr. Chen will highlight the discovery of Elpis' s multi-mechanism armor by fusing a precision-engineered IL-2 molecule to an anti-PD-L1 antibody, which has the potential to simultaneously overcome multiple resistance mechanisms within the tumor microenvironment (TME). The platform is designed to activate bystander immune cells, selectively target key immune cell types, and orchestrate the immune system for a durable anti-tumor response.
Elpis' s human bispecific armored CAR-T cells have demonstrated potent tumor regression, long persistence, and robust immune modulation across multiple solid tumor models&mdash all at significantly lower doses. These attributes reflect the platform' s potential to improve drugability, safety and support more durable clinical outcomes.
" This is an exciting moment for Elpis," said Dr. Chen. " Our multi-mechanism armor is the result of years of innovation in precision cytokine engineering empowered by mRNA display technology. By addressing both TME resistance with armored cytokine and tumor heterogeneity through bispecific targeting, our platform has the potential to deliver safer, more effective and persistent CAR-T therapies in solid tumors."
|
Event: |
PEGS Summit, Omni Boston Hotel |
|
Session Title: |
Multi-Mechanism Armored CAR-T Effectively Overcome Tumor |
|
Session Date: |
Wednesday, May 14, 12:30 pm ET |
|
Presenter: |
Dr. Yan Chen, Founder and CEO, Elpis Biopharmaceuticals |
Tob231 ( Date: 05-May-2025 10:08) Posted:
|
Why the title is " Medical Stock - Strong Shareholder" by Smallsmall ???
I think boey tio lei ... Someone mentioned RTO .... when ???
I think boey tio lei ... Someone mentioned RTO .... when ???
I would rather spend it on 300 pieces of toto quick pick tickets when the group 1 prize hit 10 million..
On second thought , better don' t cos the queue usually very long.
People will cause and swear , then buay lucky liao.
On second thought , better don' t cos the queue usually very long.
People will cause and swear , then buay lucky liao.
MrBear12 ( Date: 30-Apr-2025 18:20) Posted:
|
I'd rather spend 300 dollars on one arm bandits.
shk363 ( Date: 30-Apr-2025 18:19) Posted:
|
tikam 100 lots. potential jackpot
All mumbo jumbo...purchase is by issue of shares..for US340M.
NO FINANCIAL DETAILS YET..www
Cearbridge still can buy? after they annouce RTO
this is bridge is buried under ton and ton of mud .... hahaha mud-bridge
quite hopeless because it should not be affected by the tariff.
not if it can be resuscitated.
ciao
quite hopeless because it should not be affected by the tariff.
not if it can be resuscitated.
ciao
hear this morning they have discussion. Hope they are clearing the bridge and not burning the bridge down .... 🤣 🤣 🤣 🤣 🤣